Rayont Inc.

Equities

RAYT

US75508M1009

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 16:09:38 30/04/2024 BST			5-day change	1st Jan Change
0.1 ^USD	+19,900.00%		-.--%	-.--%

2023	Rayont Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2023	CI
2023	Rayont Inc. Announces Board Appointments	CI

Rayont, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2019

March 30, 2020 at 11:31 am

Rayont, Inc. announced earnings results for the first quarter ended December 31, 2019. For the first quarter, the company announced operating loss was USD 237,724 compared to USD 8,505 a year ago. Net loss was USD 240,930 compared to USD 9,255 a year ago. Basic loss per share from continuing operations was USD 0.02 compared to Basic EPS - Continuing Operations of USD 0 a year ago.

Latest news about Rayont Inc.

Rayont Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2023	15/05/23	CI
Rayont Inc. Announces Board Appointments	24/02/23	CI
Rayont Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2022	14/02/23	CI
Rayont Inc. Reports Earnings Results for the First Quarter Ended September 30, 2022	17/01/23	CI
Rayont Inc. Reports Earnings Results for the Full Year Ended June 30, 2022	29/12/22	CI
Rayont Inc. Auditor Raises 'Going Concern' Doubt	28/12/22	CI
Rayont Inc. Appoints Ilenna Copley as Chief Operating Officer	20/05/22	CI
Rayont Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2022	17/05/22	CI
Rayont Inc. Announces Management Changes	25/04/22	CI
Rayont Inc. Announces Board Resignations	22/04/22	CI
Rayont Inc. Announces Management Changes	01/03/22	CI
Rayont Inc. Announces Executive Changes	01/03/22	CI
Rayont Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2021	24/02/22	CI
Rayont Inc. Reports Earnings Results for the First Quarter Ended September 30, 2021	15/11/21	CI
Rayont, Inc. Reports Earnings Results for the Second Quarter Ended March 31, 2021	17/05/21	CI
Rayont Inc. Appoints Leilani Latimer as Non-Executive Director	22/04/21	CI
Rayont, Inc. Announces Appointment of Dhurata Toli as Secretary	26/03/21	CI
Rayont Inc Announces Executive Changes	25/03/21	CI
Rayont, Inc. Announces Management Changes	25/03/21	CI
Rayont Inc Appoints Reyad Fezzani as Non-Executive Director and Chairman of the Board	15/03/21	CI
Rayont, Inc. Changes its Fiscal Year End from July 31 to June 30	03/03/21	CI
Rayont : Earnings Flash (RAYT) RAYONT Reports Q4 Revenue $457,865	16/02/21	MT
Rayont, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2020	16/02/21	CI
Rayont, Inc. Announces Fiscal Year Change from September 30 to June 30, Effective December 21, 2020	21/12/20	CI
Rayont, Inc. Reports Earnings Results for the Full Year Ended September 30, 2020	18/12/20	CI

Chart Rayont Inc.

Duration

Period

More charts

Company Profile

Rayont Inc. operates in the personalized natural healthcare sector in United States and Australia. The Company uses scientific tools, such as deoxyribonucleic acid (DNA), microbiome, iridology and other tests to diagnose and personalize the prescription of natural complementary medicine products, services and treatments to its patients in the markets the Company operate. The Company produces a range of products, including proteins, green blends, sports nutrition, weight management and maintenance, and health and wellness products. The Company's subsidiaries include Rayont (Malaysia) Sdn Bhd, Rayont International (L) Limited, Rayont (Australia) Pty Ltd and Prema Life (USA) Inc.

Sector

Biotechnology & Medical Research

Calendar

13/10/2024 - Q3 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
RAYONT INC.	-.--%	4.57M
MODERNA, INC.	+51.85%	57.87B
LONZA GROUP AG	+41.42%	40.25B
IQVIA HOLDINGS INC.	-5.25%	39.94B
CELLTRION, INC.	-5.16%	28.54B
ICON PUBLIC LIMITED COMPANY	+12.79%	26.4B
ALNYLAM PHARMACEUTICALS, INC.	-20.18%	19.33B
MEDPACE HOLDINGS, INC.	+30.88%	12.4B
BIO-TECHNE CORPORATION	+0.61%	12.23B
UNITED THERAPEUTICS CORPORATION	+25.06%	12.2B

Other Biotechnology & Medical Research